DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17333335Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21893226 | https://www.ncbi.nlm.nih.gov/pubmed/20014777 | https://www.ncbi.nlm.nih.gov/pubmed/21862726 | https://www.ncbi.nlm.nih.gov/pubmed/21030469
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17333335
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/21893226 | https://www.ncbi.nlm.nih.gov/pubmed/20014777 | https://www.ncbi.nlm.nih.gov/pubmed/21862726 | https://www.ncbi.nlm.nih.gov/pubmed/21030469
Farnesol, (2E,6E)- is an isoprenoid found in many aromatic plants and is also produced in humans, where it acts on numerous nuclear receptors and has received considerable attention due to its apparent anticancer properties. Farnesol is present in many essential oils such as citronella, neroli, cyclamen, lemon grass, tuberose, rose, musk, balsam, and tolu. It is used in perfumery to emphasize the odors of sweet floral perfumes. Its method of action for enhancing perfume scent is as a co-solvent that regulates the volatility of the odorants. It is especially used in lilac perfumes. Farnesol is a natural pesticide for mites and is a pheromone for several other insects. In a 1994 report released by five top cigarette companies, farnesol was listed as one of 599 additives to cigarettes. Farnesol has been suggested to function as a chemopreventative and anti-tumor agent. Farnesol is subject to restrictions on its use in perfumery as some people may become sensitized to it, however, the evidence that farnesol can cause an allergic reaction in humans is disputed.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2051 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20014777 |
81.4 µM [IC50] | ||
Target ID: CHEMBL1287617 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21030469 |
47.0 µM [IC50] | ||
Target ID: CHEMBL2047 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21893226 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Identification of a nuclear receptor that is activated by farnesol metabolites. | 1995 Jun 2 |
|
Lovastatin induces apoptosis by inhibiting mitotic and post-mitotic events in cultured mesangial cells. | 1997 Oct 30 |
|
Evaluation of morphogenic regulatory activity of farnesoic acid and its derivatives against Candida albicans dimorphism. | 2002 Mar 25 |
|
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium. | 2004 Jul 16 |
|
Omega-hydroxylation of farnesol by mammalian cytochromes p450. | 2004 Jun 1 |
|
Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro. | 2004 Oct |
|
Cytochrome P450 expression and activities in human tongue cells and their modulation by green tea extract. | 2005 Jan 15 |
|
The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. | 2011 Feb 3 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21862726
mice were maintained for 5 wk on adiet containing 0.25%, 0.5% farnesol
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17333335
The ER-positive MCF-7 breast cancer cell line and MDAMB-231 breast carcinoma cells (ATCC HTB-26) lacking ER expression were used for activity evaluation. Cells were cultured at 37C in a humidified 95% air and 5% CO2 atmosphere. One day after seeding, the culture medium was replaced by fresh SFM containing farnesol (10-200mkM, MP Biomedicals, Aurora, OH), 17b-estradiol (Sigma, St Louis, MO), 4-hydroxytamoxifen (Sigma, St Louis, MO), the raloxifen analog LY 117,018 (a gift from Eli Lilly & Co., Indianapolis, IN), fulvestrant (ICI 182,780, Tocris, Bristol, UK), ibandronate (a gift from Hoffmann-LaRoche, Basel, Switzerland), mevastatin (Sigma, St Louis, MO), or vehicle. Cells were treated for 1–3 days, with drugs alone or in combinations. The FXR activator farnesol, a mevalonate pathway intermediate, exerts a mitogenic effect on MCF-7 cells.
Substance Class |
Mixture
Created
by
admin
on
Edited
Wed Apr 02 18:00:08 GMT 2025
by
admin
on
Wed Apr 02 18:00:08 GMT 2025
|
Record UNII |
EB41QIU6JL
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EC SCIENTIFIC COMMITTEE ON CONSUMER SAFETY OPINION |
SCCS/1459/11
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
||
|
EPA PESTICIDE CODE |
128910
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
||
|
JECFA EVALUATION |
FARNESOL
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
||
|
CFR |
21 CFR 172.515
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
42680
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
DTXSID3032389
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
EB41QIU6JL
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
DB02509
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
SUB169860
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
m5245
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | Merck Index | ||
|
1362903
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | RxNorm | ||
|
EB41QIU6JL
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
445
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
28600
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
100000159553
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
225-004-1
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
4602-84-0
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
1239
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
60597
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
D005204
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY | |||
|
FARNESOL
Created by
admin on Wed Apr 02 18:00:08 GMT 2025 , Edited by admin on Wed Apr 02 18:00:08 GMT 2025
|
PRIMARY |
Any of these components may be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |